We are experiencing some temporary issues. The market data on this page is currently delayed. Please bear with us as we address this and restore your personalized lists.
Previous Close | 0.7360 |
Open | 0.7000 |
Bid | 0.7200 x 800 |
Ask | 0.7678 x 3100 |
Day's Range | 0.6900 - 0.7500 |
52 Week Range | 0.4700 - 2.4400 |
Volume | |
Avg. Volume | 139,226 |
Market Cap | 20.902M |
Beta (5Y Monthly) | 0.36 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -0.9900 |
Earnings Date | Nov 13, 2023 - Nov 17, 2023 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 9.33 |
Subscribe to Yahoo Finance Plus to view Fair Value for EVAX
EVX-01 is Evaxion’s lead clinical asset based upon its AI-Immunology™ platform and has recently published a phase 2 clinical update confirming former phase 1 resultsPrincipal investigator Professor Adnan Khattak will walk us through this study’s encouraging results and explain its potential for revolutionizing cancer treatment COPENHAGEN, Denmark, Nov. 06, 2023 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage TechBio company specializing in th
Initial EVX-01 Phase 2 data confirms the strong Phase 1 results After undergoing EVX-01 treatment, a significant and continuous tumor reduction was observed in a metastatic melanoma patient with initial progressive disease COPENHAGEN, Denmark, Oct. 31, 2023 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage TechBio company specializing in the development of AI-Immunology™ powered vaccines, is pleased to announce initial results from the EVX-01 P
Data from Evaxion’s two personalized cancer vaccine clinical trials to be presented at the annual meeting of the Society for Immunotherapy of Cancer (SITC)These new sets of clinical data further strengthen Evaxion’s position as a pioneering cancer vaccine company COPENHAGEN, Denmark, Oct. 26, 2023 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage TechBio company specializing in developing AI-Immunology™-powered vaccines, is proud to announce th
COPENHAGEN, Denmark, Oct. 05, 2023 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage biotechnology company specializing in the development of AI-powered immunotherapies, announced today that the Company received a letter (the “Notification Letter”) on September 29, 2023 from the Listings Qualifications Department of the Nasdaq Stock Market LLC (“Nasdaq”) indicating that, for the last thirty consecutive business days, the bid price for the Compa
Evaxion's (EVAX) shares gain as it collaborates with Afrigen Biologics to develop prophylactic mRNA vaccine targeting gonorrhea, based on Evaxion's EDEN technology.
Partnership based on a highly protective vaccine candidate identified by Evaxion’s EDEN™ platformThe collaboration will access mRNA technology from the WHO and Medicines Patent Pool’s mRNA Vaccine Technology Transfer HubAfrigen responsible for the development and commercialization of the resulting mRNA vaccine in LMICs and African territories COPENHAGEN, Denmark, Sept. 20, 2023 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage biotechnology com
AI-powered target discovery for a bacterial pathogen with a high medical need where no vaccine is currently available Evaxion’s proprietary AI-platforms EDEN™ and RAVEN™ will be utilized for rapid design of a completely novel vaccine candidate capable of eliciting both a humoral (antibody) and cellular immune response to the pathogenCollaborative and co-funded project between two companies with strong scientific alignment and complementary skill sets and capabilitiesThis collaboration underlines
COPENHAGEN, Denmark, Aug. 29, 2023 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage biotechnology company specializing in the development of AI-powered immunotherapies, today announced: Evaxion has hired a new Chief Executive Officer (“CEO”) to accelerate the strategic development and execution of the vast business opportunities at hand after having matured the Company’s AI platforms over the past 15 years. “We are truly proud to announce that
Evaxion Biotech A/S (NASDAQ:EVAX) Q2 2023 Earnings Call Transcript August 22, 2023 Operator: Good day, and thank you for standing by. Welcome to the Evaxion Biotech Q2 Results Call. At this time, all participants are in a listen-only mode. After the speakers’ presentation, there will be a question-and-answer session. [Operator Instructions] Please be advised that […]
Q2 2023 Evaxion Biotech A/S Earnings Call
Symbol | Last Price | Change | % Change |
---|---|---|---|
ABVC ABVC BioPharma, Inc. | |||
RNXT RenovoRx, Inc. | |||
RNAZ TransCode Therapeutics, Inc. | |||
BTTX Better Therapeutics, Inc. | |||
BPTS Biophytis S.A. |
Symbol | Last Price | Change | % Change |
---|---|---|---|
BAVA.CO Bavarian Nordic A/S | |||
VOR Vor Biopharma Inc. | |||
EXPRS2.ST ExpreS2ion Biotech Holding AB (publ) | |||
LYEL Lyell Immunopharma, Inc. | |||
ABVC ABVC BioPharma, Inc. |
Maintains | Lake Street: to Buy | 3/31/2023 | |
Maintains | Oppenheimer: to Outperform | 11/17/2022 | |
Initiated | Oppenheimer: to Outperform | 3/2/2021 |
Dr. Neergaards Vej
5th Floor
Horsholm 2970
Denmark
45 53 53 18 50
https://www.evaxion-biotech.com
Sector(s): Healthcare
Industry: Biotechnology
Full Time Employees: 63
Evaxion Biotech A/S, a clinical-stage biotech company, engages in developing artificial intelligence-powered immunotherapies. The company develops EVX-01, a cancer immunotherapy that is in clinical Phase IIb trial for metastatic melanoma; EVX-02, a DNA-based cancer immunotherapy that is in Phase 1/2a trial for adjuvant melanoma; and EVX-03, a DNA-based immunotherapy for the treatment of various cancers. Its programs also include EVX-B1, EVX-B2, and EVX-V1, which are vaccines that are in pre-clinical stage for the treatment of bacterial and viral diseases. Evaxion Biotech A/S was incorporated in 2008 and is based in Hørsholm, Denmark.